X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Africa

Saama Launches Industry Changing Life Science Analytics Cloud

Yuvraj_pawp by Yuvraj_pawp
19th September 2017
in Africa, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Saama Technologies, Inc., a leading big data and advanced analytics solutions company, today announced the launch of its Life Science Analytics Cloud, which is designed to optimize clinical development processes and deliver outcomes by streamlining the steps of the entire clinical data journey. The suite offers a complete range of cloud-based clinical data analytics solutions for the Life Sciences industry.

As pharmaceutical companies struggle with the increase in drug development cycle times and cost overruns, pressure mounts for better command of the data that runs their business to make the drug development processes more efficient. A major challenge for any pharmaceutical company is the ability to leverage all the data it generates and has access to, due to data silos produced by a multi-vendor business model and disparate trial management systems.

Saama’s suite of analytics, powered by its Fluid Analytics Engine®, integrates multiple sources of structured and unstructured data. The cloud-based solution has pre-built capabilities for data ingestion, integration, and analysis, which can be leveraged to generate real-time business insights within weeks. Saama’s clients benefit from faster time-to-market, reduced costs, and better patient and business outcomes.

“We are committed to bringing our signature innovation and deep expertise to driving more efficient, optimized business processes and outcomes in the Life Sciences industry,” said Suresh Katta, CEO and founder of Saama Technologies. “We have been in the business of delivering superior business results for our clients and have spent considerable time and effort in developing a framework that can solve any data challenge. The launch of our Life Science Analytics Cloud marks a significant milestone in the progression of our company.”

Saama Life Science Analytics Cloud Modules
Clinical Development Optimizer: Clinical Development Optimizer (CDO) is a data lifecycle management solution that specializes in integrating and harmonizing data from disparate sources to create a clinical data lake where all the data resides, prepped and ready for analytics. CDO allows a clinical research team to assess risks across all studies and to evaluate performance based on key metrics.

Trial Planning Optimizer: Trial Planning Optimizer (TPO) is the clinical trial feasibility solution that optimizes the processes governing enrollment, investigator identification, site selection, and patient burden. TPO uses Real World Data (RWD) to identify eligible patient populations and principal investigators. TPO evaluates and quantifies the likelihood of successful patient enrollment and site selection.

Cohort Builder: Cohort Builder is the cohort generation solution that identifies patient populations based on inclusion-exclusion criteria. It organizes real-world patient information based on diagnosis, drug therapy, and procedures, to pinpoint population groups that fit specified criteria. Cohort Builder summarizes incidence rates and comorbidities of a disease and various other target metrics across a target cohort.

Market Analyzer: Market Analyzer is the commercialization analysis solution that provides the therapeutic value of clinical products, within a market basket and across geographic areas. The solution allows companies to predict the reception of a drug or treatment in the market on the basis of claims/EMR data and mapping it across similar products, market trends, and competitor activity.

Patient Pathways: Patient Pathways is the patient journey tracking solution that facilitates the evaluation of treatments, disease progression, outcomes, and total economic costs. Patient Pathways leverages RWD to provide decision-making insight into how a given disease is treated and/or managed; drug lines of therapy; treatment options and outcomes; cost of therapy; treating physicians; disease progression and complications.

“Saama’s revolutionary Life Science Analytics Cloud incorporates the latest techniques of deep learning and machine learning along with the industry’s foremost data ingestion and harmonization engine to deliver game-changing results for the industry”, said Karim Damji, SVP of Product Management and Marketing at Saama Technologies. “The launch of our Life Science Analytics Cloud is a natural progression from our previously announced innovative Clinical Data Analytics and Management as a Service announcement (CDaaS.) The analytics suite builds on top of a new consumption model for managing complexities of trial data and allows trial teams to focus on research and analysis vs. data-wrangling.”

With the release of the Life Science Analytics Cloud, Saama significantly opens up new possibilities for how to manage data in the life science industry.

Previous Post

Catalent To Acquire Cook Pharmica For $950 Million

Next Post

New Nymalize Oral Solution 10 mL Unit Dose for the Treatment of Subarachnoid Hemorrhage launched by Arbor Pharma

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

New Nymalize Oral Solution 10 mL Unit Dose for the Treatment of Subarachnoid Hemorrhage launched by Arbor Pharma

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In